Diabetes patients can be a target for chronic kidney disease but can also take aim back: This is the message from AstraZeneca’s new Farxiga TV ad, which is pushing the drug’s new CKD label. There is ...
AstraZeneca PLC AZN announced that the FDA has granted a Fast Track designation to its SGLT2 inhibitor Farxiga (dapagliflozin) for reducing the risk of hospitalization for heart failure (hHF) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback